Top 3 Factors Shaping the Pharmaceutical Intermediates Market
Increasing Production expected to drive the Pharmaceutical Intermediates market
Increasing demand of various pharmaceutical intermediates and APIs due to increasing production of the final drug formulation is expected to fuel the growth of the market. Globally, various manufacturing companies from the pharmaceutical as well as biopharmaceutical industries are focusing on improving their geographical product footprint.
Manufacturers are focusing enhancing their product reach through various distribution channels in different countries across the world which is resulting in increasing production capacity. E.g. in January 2019, Fujifilm plans to boost its overall production capacity by expanding its production facility at North Carolina.
During 2015-2017, there were more than 130 mergers and acquisitions in the pharma industry, which involved contract manufacturing organisations with operations in APIs and pharmaceutical intermediates.
Increasing Prevalence of Chronic Diseases is expected to drive the Pharmaceutical Intermediates market
The rapidly increasing prevalence of chronic diseases and the growth of the aging population across the world are among factors that are expected to increase the need for drug formulations for the management of chronic diseases. For example, according to the World Health Organization (WHO), the prevalence of diabetes has surged from 108.0 million in 1980 to 422.0 million in 2014, and the number is rising rapidly.
According to the World Health Organization (WHO), the prevalence of chronic diseases is expected to increase by 57.0% by 2020, which indicates that a significant percentage of population is suffering from chronic diseases.
Increasing Investments in manufacturing expected to fuel growth in pharmaceutical intermediates market
Leading pharmaceutical companies in pharmaceutical intermediates market have announced their intentions to invest in manufacturing facilities due to various reasons such as to enhance the production capacity of pharmaceutical intermediates, reduce corporate tax rate (due to recent tax reforms in the U.S.), and to increase their global footprints as well as their presence in emerging markets.
For example, in July 2018, Pfizer announced its plan to invest around US$ 465.0 million to build a sterile injectable plant in Portage, Michigan. This step is a part of its announcement that it had made earlier in 2018 about its plans to invest around US$ 5.0 billion in a U.S.-based capital project due to the recent corporate tax reforms in the country.
Pharmaceutical Intermediates Market Structure Analysis
- The global Pharmaceutical Intermediates market is categorised by small independent companies.
- Some of the prominent companies in the Pharmaceutical Intermediates market include Chiracon GmbH, BASF SE, Cambrex Corporation, etc. Most of the companies are focusing on the increasing their product portfolio offering by offering different types pharmaceutical intermediates
- The pharmaceutical intermediates market is fragmented market and majority of the manufacturing companies located in the East Asia and South Asia due to lower production cost as compared to regions such as Europe and North America
Pharmaceutical Intermediates – Increased Care Seeking Rates and The Need for Generics
Incessant rise of chronic ailments vis-à-vis growing elder demographic has grown on the need for branded, generics as well as branded generics drugs, prompting pharmaceutical intermediates manufacturers to boost production capacities. The search for care has been increasingly palpable worldwide, fuelling the requirement for generics, specialty active pharmaceutical ingredients (API's) and quality drugs, in turn favouring sales of pharmaceutical intermediates.
Market Set to Grow 1.5X between 2019 and 2029
Innovative strategies and work practices of the industry in helping care setting expand their remedial offerings continue to augur well for the pharmaceutical intermediates landscape. While patent expiries remain key development enablers, clinical studies on new therapeutic measures for various ailments are driving advancements in pharmaceutical intermediates.
Stakeholders Vie to Tap Opportune Potential of Emerging Markets
Stakeholders continue to uptake the relatively greater prevalence of chronic ailments and the need for generic drugs and personalized treatment in emerging markets. East Asia continues to lead the pharmaceutical intermediates landscape, with sales growing at a relatively higher rate.
How Growth will Unfold
CMOs/CROs are expected to account for leading shares of the pharmaceutical intermediates market, as these pose a huge demand in biopharmaceutical contract manufacturing and are used as essential ingredients in medicinal chemistry and custom synthesis.
Growth rate sales in research laboratories is expected to be similar to those in CMOs/CROs, however revenues will remain sluggish. Demand for pharmaceutical intermediates in biotech & pharma companies will also remain significant.
PHARMACEUTICAL INTERMEDIATES MARKET TAXONOMY
The global pharmaceutical intermediates market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach in front of the reader.?
By Product Type
- Chemical Intermediates
- Bulk Drug Intermediates
- Chiral Intermediates
- Achiral Intermediates
- Custom Intermediates
By Category
- Branded Drugs
- Generic Drugs
By Application
- Analgesics
- Anti-Infective Drugs
- Cardiovascular Drugs
- Oral Antidiabetic Drugs
- Antimicrobial Drugs
- Others
By End User
- Biotechnology and Pharmaceutical Companies
- Research Laboratories
- Contract Manufacturing Organizations / Contract Research Organizations
By Region
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- MEA
Need specific information?
In the news
by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights
Our Clients
View Our Reports from Healthcare
View Reports